publication date: Jan 10, 2014
AVEO Oncology said that data from a planned interim analysis of the phase II BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population.
BATON-CRC, led by Astellas, is an open-label, randomized phase II study with a primary endpoint evaluating the superiority of tivozanib in combination with modified FOLFOX6, compared to bevacizumab in combination with modified FOLFOX6 as first-line treatment in patients with advanced metastatic CRC.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.